5-Amino-1MQ: A Tracking Guide for an NNMT Inhibitor

5-Amino-1MQ is a small molecule, not a peptide, but it shows up frequently in peptide-adjacent self-experimenter circles. It is an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that becomes elevated in adipose tissue with obesity and aging. Most of the interest comes from preclinical work suggesting that inhibiting NNMT raises cellular NAD+ availability and shifts adipocyte energetics. Human data is very limited, and nothing is approved by major regulators.

What it is supposed to do

NNMT consumes methyl groups from SAM and produces 1-methylnicotinamide. In animal models, blocking NNMT in adipose tissue is associated with reduced fat mass, improved insulin sensitivity, and changes in muscle stem cell function. The translation of these effects to humans is still an open question.

Typical protocol shape

• Route: oral capsule
• Frequency: once daily, usually morning with or without food
• Dose: self-reports cluster around 50–150 mg/day; no clinical dose has been established in humans
• Duration: 8–12 week blocks are common, with a break afterward

Because this is a research compound and not approved for human use, sourcing varies in quality. Treat anything you take as if the label might be wrong.

What to track daily

• Morning fasted weight
• Resting heart rate on waking
• Subjective energy (1–10) mid-morning and mid-afternoon
• Hunger rating before lunch
• Sleep duration and any wake-ups

What to track weekly

• Waist at the navel, three measurements, averaged
• Hip circumference
• Body composition if you have a consistent method (DEXA, InBody, calipers)
• Resistance training performance on a chosen lift
• Mood and motivation summary

Bloodwork worth doing

If you want to evaluate metabolic effects rather than guess, a baseline and 10–12 week panel is reasonable:

• Fasting glucose and insulin (HOMA-IR)
• HbA1c
• Lipid panel
• Liver enzymes (ALT, AST)
• Kidney markers (creatinine, eGFR)

Realistic expectations

Most public self-reports describe modest appetite changes and a slow shift in body composition over months, not dramatic weight loss. Anyone reporting rapid changes is likely conflating it with diet or training adjustments. The honest framing is: animal data is promising, human data is thin, side-effect profile in humans is not well characterized.

Common mistakes

• Stacking it with a new training program and a new diet at the same time, then attributing results to the compound
• Skipping baseline bloodwork
• Running it continuously for many months without a break
• Assuming oral bioavailability and dosing translate cleanly from rodent studies

A tracking template

• Week 0: baseline bloodwork, body measurements, photos, two-week food and training log
• Weeks 1–4: hold diet and training constant; log daily metrics in Peptide IA
• Weeks 5–8: continue, repeat measurements at week 8
• Weeks 9–12: final block, repeat bloodwork and measurements at week 12
• Weeks 13–16: washout, repeat measurements at week 16 to see what reverts

Bottom line

5-Amino-1MQ is an interesting research target with a coherent mechanism and almost no human safety or efficacy data. If you choose to self-experiment, the value is in the tracking, not the compound. A clean baseline, controlled variables, and a real washout phase are what let you say anything useful about your own response.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.